01—Abstract
Summary
Summary of the 8-K filed August 29, 2024. Cited figures are marked; the original filing is the authoritative source.
On August 29, 2024, BeiGene, Ltd. (ONC, now BeOne Medicines) filed this Form 8-K to furnish supplemental financial information tied to its 2024 Interim Report for the six months ended June 30, 2024.
That report was filed with the Shanghai Stock Exchange's STAR Market under PRC rules. The 8-K contains no new headline U.S. results such as revenue, net loss, or EPS. Its substance is a breakdown of research and development (R&D) expenses by key product and project, presented under U.S. GAAP, along with a summary of the differences between PRC GAAP and U.S. GAAP.
The Chinese-language STAR report is not part of this filing and is not deemed filed with the SEC. The R&D allocation shows total R&D expense of $915.1 milliona for the first half of 2024, up about 10% from $831.3 million a year earlier. External R&D rose about 17% to $330.1 million, including $82.5 million in R&D collaboration projects (up from $23.3 million).
Internal R&D grew about 6% to $585.0 millionb. The mix shifted toward newer programs. Bcl-2 (BGB-11417) expense more than doubled to $38.6 million, and CDAC (BGB-16673) rose to $5.7 million from $1.1 million.
Expense for the commercial anchors fell: zanubrutinib dropped about 22% to $62.9 millionc and tislelizumab about 27% to $34.5 million. Pamiparib, ociperlimab, and OX40 also declined.
For investors, the main takeaways are the continued growth of total R&D spend, the rising weight of collaboration and early-stage programs, and the lower R&D investment behind the two established products. Because the document is a regulatory supplement rather than an earnings release, it is best read alongside the company's U.S. quarterly filings for revenue, profitability, and pipeline milestones.
02—Key points
Key Highlights
- Total R&D expense for H1 2024 was $915.1 million, up about 10% from $831.3 million in H1 2023.
- External R&D rose about 17% to $330.1 million, driven by R&D collaboration projects, which grew to $82.5 million from $23.3 million.
- Internal R&D increased about 6% to $585.0 million, making it the larger share of total R&D spend.
- Bcl-2 (BGB-11417) R&D expense more than doubled to $38.6 million from $17.5 million, signaling increased investment in this program.
- Zanubrutinib R&D expense fell about 22% to $62.9 million, and tislelizumab fell about 27% to $34.5 million.
- The filing contains no new headline U.S. GAAP revenue, net income, or EPS figures; it is a PRC-mandated supplemental disclosure furnished under Item 2.02 and not deemed filed under Section 18 of the Exchange Act.
- PRC GAAP differs from U.S. GAAP in share-based compensation (accelerated vs. straight-line attribution), interim income tax calculation (jurisdiction-by-jurisdiction vs. single annual rate), and lease accounting (separate interest and depreciation presentation under PRC GAAP).
03—Questions
Frequently Asked Questions
Why did BeiGene file this 8-K if it contains little new financial performance data?
The company filed its 2024 Interim Report with the STAR Market of the Shanghai Stock Exchange, which requires additional disclosures under PRC securities rules. Because the company is a U.S.-listed issuer, it furnished the U.S. GAAP R&D breakdown and PRC/U.S. GAAP difference summary to the SEC as Exhibit 99.1 for investors who rely on U.S. filings.
Did R&D spending increase or decrease in the first half of 2024?
Total R&D expense increased about 10%, from $831.3 million to $915.1 million. External R&D rose about 17% to $330.1 million, while internal R&D rose about 6% to $585.0 million.
Which programs saw the largest changes in R&D spending?
Bcl-2 (BGB-11417) rose about 120% to $38.6 million, and CDAC (BGB-16673) rose to $5.7 million from $1.1 million. R&D collaboration projects increased to $82.5 million from $23.3 million. Zanubrutinib (down about 22%), tislelizumab (down about 27%), and pamiparib (down about 63%) declined.
Does this filing change the company's reported revenue or profitability?
No. The filing does not report revenue, net loss, or EPS. The figures are supplemental R&D allocations, and investors should consult the company's U.S. GAAP periodic reports for its financial results.
Are the STAR Market report and the Shanghai Stock Exchange website part of the SEC filing?
No. The company states that the STAR Interim Report, which is in Chinese only, and the Shanghai Stock Exchange website are not part of the 8-K and are not deemed filed or furnished with the SEC.
04—Continue